Comparison of two different GnRH analogs' impact on final height in girls with early puberty: Triptorelin acetate <i>vs.</i> leuprolide acetate.

Aka S., Abali S., Taskin A., Bengur F. B., Semiz S.

Acta endocrinologica (Bucharest, Romania : 2005), cilt.16, sa.4, ss.402-408, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.4183/aeb.2020.402
  • Dergi Adı: Acta endocrinologica (Bucharest, Romania : 2005)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE
  • Sayfa Sayıları: ss.402-408
  • Anahtar Kelimeler: Early puberty, GnRH analog treatment, Triptorelin acetate, Leuprolide acetate, body mass index, final height, BODY-MASS INDEX, CENTRAL PRECOCIOUS PUBERTY, GONADOTROPIN-SUPPRESSIVE THERAPY, ADULT HEIGHT, HORMONE ANALOGS, GROWTH, REFERENCES, AGONISTS, PATTERN, WEIGHT
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Context. GnRHa treatment has been a standard of care in progressive early puberty (EP). Choice of the GnRHa formulation is dependent on the preference of the clinician.